logo
Georgia hospital says it's following state law in continuing pregnancy of woman on life support

Georgia hospital says it's following state law in continuing pregnancy of woman on life support

CBC16-05-2025
Social Sharing
A pregnant woman in Georgia who was declared brain-dead after a medical emergency has been on life support for three months to let the fetus grow enough to be delivered, a move her family says a hospital told them was required under the state's strict anti-abortion law.
Members of Adriana Smith's family say Emory University Hospital doctors have told them they are not allowed to stop or remove the devices that are keeping her breathing because state law bans abortion after cardiac activity can be detected — generally around six weeks into pregnancy.
With the due date still more than three months away, it could be one of the longest such pregnancies. Her family is upset that Georgia's law that restricts abortion once cardiac activity is detected doesn't allow relatives to have a say in whether a pregnant woman is kept on life support.
The law was adopted in 2019 but not enforced until after Roe v. Wade was overturned in the 2022 Dobbs v. Jackson Women's Health Organization ruling by the Supreme Court, which opened the door to state abortion bans.
Smith, a 30-year-old mother and nurse, was declared brain-dead in February, her mother, April Newkirk, told Atlanta TV station WXIA.
Newkirk said Smith is now 21 weeks pregnant. Removing breathing tubes and other life-saving devices would likely kill the fetus.
Emory Healthcare said it could not comment on an individual case because of privacy rules, but released a statement saying it "uses consensus from clinical experts, medical literature, and legal guidance to support our providers as they make individualized treatment recommendations in compliance with Georgia's abortion laws and all other applicable laws. Our top priorities continue to be the safety and wellbeing of the patients we serve."
Twelve states are enforcing bans on abortion at all stages of pregnancy and three others have bans like Georgia's that kick in after about six weeks.
Like the others, Georgia's ban includes an exception if an abortion is necessary to maintain the woman's life.
Legal confusion over rights of fetus
Newkirk said her daughter had intense headaches more than three months ago and went to Atlanta's Northside Hospital, where she received medication and was released. The next morning, her boyfriend woke to her gasping for air and called 911. Emory University Hospital determined she had blood clots in her brain and she was declared brain-dead.
Smith's family, including her five-year-old son, still visit her in the hospital.
Newkirk told WXIA that doctors told the family that the fetus has fluid on the brain and that they're concerned about his health.
"She's pregnant with my grandson. But he may be blind, may not be able to walk, may not survive once he's born," Newkirk said.
She has not said whether the family wants Smith removed from life support.
Monica Simpson, executive director of SisterSong, the lead plaintiff in a lawsuit challenging Georgia's abortion law, said the situation is problematic.
"Her family deserved the right to have decision-making power about her medical decisions," Simpson said in a statement. "Instead, they have endured over 90 days of retraumatization, expensive medical costs, and the cruelty of being unable to resolve and move toward healing."
Lois Shepherd, a bioethicist and law professor at the University of Virginia, said she does not believe life support is legally required in this case.
But she said whether a state could insist Smith remains on life support is uncertain since the overturning of Roe, which found that fetuses do not have the rights of people.
"Pre-Dobbs, a fetus didn't have any rights," Shepherd said. "And the state's interest in fetal life could not be so strong as to overcome other important rights, but now we don't know."
Complications frequent in known cases
Brain death in pregnancy is rare. Rarer still are cases in which doctors aim to prolong the pregnancy after a woman is declared brain-dead.
A 2021 review scoured medical literature going back decades for cases in which doctors declared a woman brain-dead and aimed to prolong her pregnancy. It found 35.
Of those, 27 resulted in a live birth, the majority either immediately declared healthy or with normal follow-up tests. But Dr. Vincenzo Berghella, who co-authored the study, also cautioned that the Georgia case was much more difficult because the pregnancy was less far along when the woman was declared brain-dead.
In the 35 cases he studied, doctors were able to prolong the pregnancy by an average of just seven weeks before complications forced them to intervene.
"It's just hard to keep the mother out of infection, out of cardiac failure," said Berghella, director of maternal fetal medicine at Thomas Jefferson University in Philadelphia.
Berghella also found a case from Germany that resulted in a live birth when the woman was declared brain-dead at nine weeks of pregnancy — about as far along as Smith was when she died.
Georgia's law confers personhood on a fetus. Those who favour personhood say fertilized eggs, embryos and fetuses should be considered people with the same rights as those already born.
Georgia state Sen. Ed Setzler, a Republican who sponsored the 2019 law, said he supported Emory's interpretation.
"I think it is completely appropriate that the hospital do what they can to save the life of the child," Setzler said. "I think this is an unusual circumstance, but I think it highlights the value of innocent human life. I think the hospital is acting appropriately."
WATCH l Then-VP candidate Tim Walz on the death of Georgia woman Amber Thurman:
Letting states decide abortion rules puts American lives in danger, Walz says
8 months ago
Duration 1:41
During the CBS News Vice-Presidential Debate on Tuesday, Democratic nominee Tim Walz countered Republican nominee J.D. Vance's comment that states should make their own decisions about abortion by referring to the case of a Georgia woman who died while trying to access a legal procedure out of state. 'There's a very real chance, had Amber Thurman lived in Minnesota, she would be alive,' Walz said.
Setzler said he believes it is sometimes acceptable to remove life support from someone who is brain-dead, but that the law is "an appropriate check" because the mother is pregnant. He said Smith's relatives have "good choices," including keeping the child or offering it for adoption.
Georgia's abortion ban has been in the spotlight before.
Last year, ProPublica reported that two Georgia women died after they did not get proper medical treatment for complications from taking abortion pills. The stories of Amber Thurman and Candi Miller entered the presidential race, with Democrat Kamala Harris saying the deaths were the result of the abortion bans that went into effect in Georgia and elsewhere after Dobbs.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Globe and Mail

time17 minutes ago

  • Globe and Mail

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherapy development. to develop enhanced analytics and visualization tools, for the PredicTcell model to support its internal R&D teams. WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen ('Tevogen Bio Holdings Inc.' or 'Company') (Nasdaq: TVGN) today announced that its artificial intelligence initiative, is expanding its collaboration with Microsoft (Nasdaq: MSFT) and Databricks, to build the beta version of its foundational PredicTcell model. Powered by the Databricks Data Intelligence Platform and backed by their innovative engineering teams, has begun curating a dataset focused on oncology. The dataset, aggregated with the initial virology dataset. aims to improve upon the accuracy of the alpha version of PredicTcell model. This next phase of development builds on recently published international patent application (WO 2025/129197), which outlines novel machine learning systems for predicting immunologically active peptides, a critical step in developing targeted therapies for cancers and infectious diseases. 'We have been extremely fortunate to work with such great organizations like Microsoft and Databricks to build the alpha version of our foundational AI model,' said Mittul Mehta, Chief Information Officer and Head of 'Oncology represents one of the most impactful areas for AI in drug discovery, given the complexity of the disease and the limited availability of high-quality datasets.' Forward Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Vitiligo Pipeline Outlook Report 2025: Key 18+ Companies and Breakthrough Therapies Shaping the Future Landscape
Vitiligo Pipeline Outlook Report 2025: Key 18+ Companies and Breakthrough Therapies Shaping the Future Landscape

Globe and Mail

timean hour ago

  • Globe and Mail

Vitiligo Pipeline Outlook Report 2025: Key 18+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, ' Vitiligo Pipeline Insight, 2025 ' report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Vitiligo pipeline landscape. It covers the Vitiligo pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Vitiligo pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Vitiligo Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Vitiligo Pipeline Outlook Report Key Takeaways from the Vitiligo Pipeline Report In August 2025, Incyte Corporation announced a study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo. In July 2025, Clinuvel Inc. conducted a CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone. DelveInsight's Vitiligo pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Vitiligo treatment. The leading Vitiligo Companies such as Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others. Promising Vitiligo Pipeline Therapies such as Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide and others. Discover how the Vitiligo treatment paradigm is evolving. Access DelveInsight's in-depth Vitiligo Pipeline Analysis for a closer look at promising breakthroughs @ Vitiligo Clinical Trials and Studies Vitiligo Emerging Drugs Profile Afamelanotide: Clinuvel, Inc. Afamelanotide, developed by Clinuvel, Inc., is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) designed to promote skin pigmentation in individuals with vitiligo. It works by activating melanocortin 1 receptors (MC1R) on melanocytes, stimulating melanin production and distribution in depigmented areas of the skin. Afamelanotide is administered via a subcutaneous implant, offering a systemic approach that may enhance repigmentation, particularly when used in combination with controlled UV light therapy. Its mechanism addresses the underlying pigment loss in vitiligo, aiming to restore skin tone more uniformly and effectively. Currently, the drug is in Phase III stage of its development for the treatment of Vitiligo. VYN201: Vyne Therapeutics Inc. Repibresib is a pan-bromodomain BET inhibitor designed to be locally administered as a 'soft' drug to address diseases involving multiple, diverse inflammatory cell signaling pathways, while providing low systemic exposure. BET proteins play a key role in regulating gene transcription via epigenetic interactions ('reading'). Recent research has identified a key role for these proteins in regulating activation of immune cells, including T cells and B cells, and subsequent inflammatory and fibrotic processes. As epigenetic readers, BET proteins regulate the recruitment of transcriptional factors that are key to the production of several pro-inflammatory cytokines. BET inhibitors have the potential to treat a range of immuno-inflammatory and fibrotic diseases by blocking pro-inflammatory cytokine transcription, with additional potential in myeloproliferative neoplastic disorders. In addition to demonstrating clinical proof-of-concept in vitiligo, repibresib has produced consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity in several preclinical models (using several different routes of administration). Currently, the drug is in Phase II stage of its development for the treatment of Vitiligo. FB102: Forte Biosciences, Inc. FB102 is a proprietary molecule with potentially broad autoimmune and autoimmune-related applications. The Company's FB102 program aims to address key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. Significant reductions in NK cell pharmacodynamic marker of FB102 mechanism was observed supporting the in vitro as well as the NHP data and mechanism of action of FB102. A phase 1 healthy volunteer SAD/MAD study was successfully completed and demonstrated a good safety profile. Currently, the drug is in Phase I stage of its development for the treatment of Vitiligo. The Vitiligo Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Vitiligo with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vitiligo Treatment. Vitiligo Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Vitiligo Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vitiligo market. Get a detailed analysis of the latest innovations in the Vitiligo pipeline. Explore DelveInsight's expert-driven report today! @ Vitiligo Unmet Needs Vitiligo Companies Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others. Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Vitiligo Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Vitiligo Therapies and key Developments @ Vitiligo Market Drivers and Barriers, and Future Perspectives Scope of the Vitiligo Pipeline Report Coverage- Global Vitiligo Companies- Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others. Vitiligo Pipeline Therapies- Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide and others. Vitiligo Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Vitiligo Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Vitiligo drug development? Find out in DelveInsight's exclusive Vitiligo Pipeline Report—access it now! @ Vitiligo Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Vitiligo: Overview Pipeline Therapeutics Therapeutic Assessment Vitiligo– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Afamelanotide: Clinuvel, Inc. Mid Stage Products (Phase II) VYN201: Vyne Therapeutics Inc. Early Stage Products (Phase I) FB102: Forte Biosciences, Inc. Preclinical and Discovery Stage Products Drug Name: Company Name Inactive Products Vitiligo Key Companies Vitiligo Key Products Vitiligo- Unmet Needs Vitiligo- Market Drivers and Barriers Vitiligo- Future Perspectives and Conclusion Vitiligo Analyst Views Vitiligo Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

A $2.5 billion pledge makes women's health a priority in Gates Foundation spend-down
A $2.5 billion pledge makes women's health a priority in Gates Foundation spend-down

Globe and Mail

time2 hours ago

  • Globe and Mail

A $2.5 billion pledge makes women's health a priority in Gates Foundation spend-down

Innovations on the horizon in women's health show what's possible with more investment. With the help of ultrasound equipment powered by artificial intelligence, frontline health care workers may be able to track the progress of developing embryos with a minimum of training. And birth control injections that last six months could give women more control over reproduction. Those are just two potential breakthroughs out of more than 40 the Gates Foundation intends to support through a five-year, $2.5 billion commitment on women's health research and development, more than triple the amount it has spent on women's health innovation over the past five years. 'Many of the most pressing conditions impacting women still remain understudied, underdiagnosed, and overlooked,' said Ru-fong Joanne Cheng, director of Women's Health Innovations at Gates. A very small share of medical research funding supports the study of health specific to women, including gynecological and menstrual health, obstetric care, contraceptive innovation, sexually transmitted infections, and maternal health and nutrition, the foundation said. It cited a 2021 McKinsey and Company study that found 1% of all medical research, setting aside cancer research, goes toward women's health. The foundation framed the commitment as part of its May announcement that it would spend down its assets over the next 20 years and concentrate much of its support on global health. While much of the research funded over the next five years will benefit women worldwide, the foundation said, the need is most acute in sub-Saharan Africa and Southeast Asia. By devoting billions to women's health, the foundation has signaled it intends to continue to invest in the cause following the 2024 departure of Melinda French Gates, who led the foundation's support of girls' and women's health. Since her divorce from Bill Gates, French Gates has committed more than $1 billion to improve women's physical and mental health, provide more economic opportunity to women, and increase their political sway. The announcement follows a U.S. pullback of support for global maternal health programs during the first seven months of the Trump administration. The shuttering of the U.S. Agency for International Development and program reductions at the Centers for Disease Control have sunset programs focused on women's health. According to a March internal USAID memo, the agency's closure will stop services for 16.8 million pregnant women annually. In April, the World Health Organization said that the 40 percent decline in maternal deaths from 2000 to 2023 has been put at risk because of aid cuts. 'We need both innovation and delivery' While the foundation continues to focus on the delivery of health care globally in an era of governmental retreat, the $2.5 billion will focus squarely on research needed to save lives, Anita Zaidi, president of Gates's Gender Equality Division, said on a press call Monday to discuss the announcement. 'This is an innovation-focused announcement,' she said. 'We need both innovation and delivery.' It's important to remember that the U.S. Food and Drug Administration has only been required to test novel drugs on women in clinical trials since 1993, and many tests are still only done on men, said Katy Brodsky Falco, founder of the Foundation for Women's Health, which plans to make $5 million in research grants this year. With Gates getting behind research and development of women's health with such a large commitment, others may follow, Brodsky Falco said. 'Hopefully it will bring the issue to the top of the conversation among private donors and family foundations, even if they otherwise haven't supported this type of work,' she said. Moses Obimbo Madadi, professor at the University of Nairobi, noted that postpartum hemorrhaging causes about 3,000 deaths annually in Kenya. If men were the victims, he said, a G7 conference would be called to find a solution, but research on the subject has largely been ignored because it claims the lives of women. 'We've treated this as a peripheral issue other than making it a centerpiece of our research,' he said, calling the Gates commitment a 'very good starting point.' _____

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store